Ismail, M.A., Kamal, A.M., Ghobashy, S., Al Baz, A.G., & Roshdy, M. (2015). Comparison of pain control during Trus guided biopsies between basal peri-prostatic local infiltration anesthesia versus combined topical anal lignocaine ointment and local infiltration anesthesia. Journal of the Egyptian Society of Parasitology, 45, 285–289.
To compare two techniques for pain relief with transrectal ultrasonography (TRUS)-guided biopsies
Patients undergoing prostate biopsies were randomized to receive either local infiltration anesthesia alone or a combination of local anesthesia and lignocaine 5% ointment to the anal rind, canal, and anterior rectal wall. Patients were asked to rate pain during insertion, during infiltration, and after biopsy.
Randomized trial
Patients who received a combination of local and topical anesthesia reported significantly less pain (p = 0.005) at all stages of the procedure.
The combination of a local anesthetic infusion with a topical anesthetic may provide better pain control during biopsy.
The combination of anesthetic infiltration and a local topical anesthetic may reduce pain during biopsy.
Ishizuka, M., Nagata, H., Takagi, K., & Kubota, K. (2013). Needleless closed system does not reduce central venous catheter-related bloodstream infection: A retrospective study. International Surgery, 98, 88–93.
To determine whether a needleless closed system (NCS) is superior to the Luer cap system (LCS) in regards to the prevention of catheter-related bloodstream infection.
This was a retrospective study comparing the length of time from central venous catheter (CVC) insertion to the development of central-line associated blood stream infection (CLABSI) using LCS and then switching to NCS.
Retrospective analysis
The authors measured the time interval from CVC insertion to the development of CLABSI and compared a group of patients using LCS to a group using NCS. Centers for Disease Control (CDC) guidelines were used to define and diagnose CLABSI.
Using the Kaplan-Meier estimate and the log-rank test, the authors found that there was no significant difference between the LCS group and the NCS group in the time interval from CVC insertion to onset of CLABSI. Similarly, there was no significant difference in the incidence of CLABSI (p = 0.3), blood culture positivity (p = 0.836), and CVC tip positivity (p = 0.116) between the two groups.
There was no significant difference between the two groups in regard to blood culture positivity, CVC tip culture positivity, or the incidence of CLABSI. NCS did not demonstrate superiority in terms of prevention of CLABSI.
Although they were not shown to reduce CLABSI, NCSs are still recommended as a means of preventing needle-stick injuries.
Ishihara, M., Iihara, H., Okayasu, S., Yasuda, K., Matsuura, K., Suzui, M., & Itoh, Y. (2010). Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients. Supportive Care in Cancer, 18, 1531–1538.
In part 1, patients who were admitted and receiving opioids were surveyed for use of prophylactic laxatives to prevent constipation.
In part 2, prescribers were given drug information, orders were reviewed, and patients were educated about laxatives to manage constipation.
Patients were undergoing the active treatment phase of care.
This was a retrospective survey followed by an interventional study.
Laxative use prophylactically reduced the incidence of constipation in patients taking opioid therapy but did not completely prevent it.
Laxative prophylaxis is beneficial to reduce the risk of opioid-induced constipation. Proactive interventions to increase laxative use may be beneficial to patients.
Ishihara, M., Ikesue, H., Matsunaga, H., Suemaru, K., Kitaichi, K., Suetsugu, K., . . . Japanese Study Group for the Relief of Opioid-Induced Gastrointestinal Dysfunction. (2012). A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clinical Journal of Pain, 28, 373–381.
To evaluate the effectiveness of prophylactic laxatives and antiemetics on constipation, nausea, and vomiting in patients with cancer receiving opioids for the first time.
Medical records were reviewed from 2009 to 2010 for patients experiencing constipation, nausea, or vomiting during the first week of opioid analgesic administration. Number of stools recorded was used in the analysis. Constipation was defined as a stool-free interval of at least 72 hours during the first week. One episode of vomiting was counted as evidence of vomiting. Nausea grading was recorded for seven days.
This was a descriptive, retrospective study.
National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE), version 4.0, for nausea grading
Use of prophylactic laxatives in patients receiving opioids for the first time was effective in reducing the risk and prevalence of constipation.
Findings suggested use of prophylactic laxatives can reduce opioid-induced constipation during the first week in which patients receive opioids. Findings also suggested older patients may be at greater risk for opioid-induced constipation. Nurses can ensure that prophylactic regimens to prevent constipation are suggested for patients beginning opioid use and older adult patients.
Ishido, K., Higuchi, K., Azuma, M., Sasaki, T., Tanabe, S., Katada, C., ... & Koizumi, W. (2016). Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: A randomized crossover phase II trial (KDOG 1002). Anti-Cancer Drugs, 27, 884–890.
To gain evidence regarding which regimen should be used for the management of highly emetogenic chemotherapy (HEC) induced chemotherapy-induced nausea and vomiting (CINV)
Patients were randomly assigned to the order of receiving either palonosteron and dexamethasone (PD) or aprepitant, granisetron, and dexamethasone (AGD) prophylaxis. The PD regimen was 0.75 mg palonosetron and 13.2 mg dexamethasone IV prior to treatment and 8 mg oral dexamethasone 24 and 48 hours later. The AGD regimen was 125 mg oral aprepitant and 3 mg granisetron and 6.6 mg dexamethasone IV before treatment, followed by 80 mg aprepitant and 4 mg dexamethasone at 24 and 48 hours. During the second cycle, patients were crossed over to the alternative regimen. During cycle 1, CINV and the use of rescue antiemetics were evaluated. After crossover, patients were asked which treatment was more effective and preferred. Rescue medications were metoclopramide or prochlorperazine.
No significant differences existed between treatment regimens for complete response in the acute phase. The complete response (CR) rate was higher in the delayed (p = 0.025) and overall phases (p = 0.025) in the regimen including aprepitant. Less than 40% with either treatment had no nausea. FLIE scores indicating impact on daily life showed that more patients in the aprepitant-based regimen group were not affected by nausea (p = 0.014). Forty-one percent indicated preference for AGD, 19.7% preferred PD, and 39.3% indicated no preference.
Findings suggest that a CINV prophylactic regimen containing an NK1—in this case, aprepitant—was more effective in preventing CINV than a regimen of palonosetron and dexamethasone alone.
Findings support the use of a triple drug regimen of a 5HT3, NK1, and dexamethasone for patients receiving HEC. Nausea in the delayed phase continues to be an ongoing problem that is not completely relieved with these regimens. Further research is needed to identify other adjuvant medications to address nausea.
Ishibashi, K., Okada, N., Miyazaki, T., Sano, M., & Ishida, H. (2010). Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. International Journal of Clinical Oncology, 15, 82–87.
To evaluate the effectiveness of calcium/magnesium (Ca/Mg) infusions in reducing the incidence and severity of oxaliplatin-related neurotoxicity and to evaluate the effects of Ca/Mg infusions on progression-free survival and platinum plasma levels in patients with colorectal cancer
Patients with metastatic colorectal cancer were randomized and double-blinded to receive mFOLFOX6 with a Ca/Mg infusion (100 ml of 5% glucose-containing calcium gluconate of 850 mg and magnesium sulfate of 720 mg) before and after the administration of oxaliplatin or mFOLFOX6 with placebo (100 ml of 5% glucose alone) before and after administration of oxaliplatin (85 mg/m2) every two weeks for six cycles. Prior to administration, patients were assessed for adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, by nurses or pharmacists.
Prospective, randomized, double-blind, controlled trial in patients with metastatic colorectal cancer receiving mFOLFOX6
Ca/Mg infusion prior to and after mFOLFOX6 did not reduce the incidence of grade 1–3 neurotoxicity using two different standardized measures for neurotoxicity (DEB-NTS and CTCAE) after the completion of six cycles; response rates, disease control rates, and median survival times were not significantly different between groups. No significant differences existed in the plasma platinum levels between groups (Ca/Mg versus placebo) at any time point using the pre-established significance value of p < 0.05. Also, no significant difference in plasma platinum levels existed in those who developed grade 2 neuropathy compared to those who developed less severe neuropathy (DEB-NTS). When comparing those who achieved a partial or complete remission with mFOLFOX6 to those who achieved no response, plasma platinum levels did not differ, suggesting that calcium and magnesium infusions did not influence the efficacy of mFOLFOX6 chemotherapy.
Ca/Mg infusions before and after oxaliplatin did not reduce the incidence or severity of neurotoxic symptoms in patients with metastatic colorectal receiving mFOLFOX6.
The administration of Ca/Mg before and after oxaliplatin as a preventive measure to reduce the incidence or severity of oxaliplatin-related peripheral neuropathy in patients with colorectal cancer receiving mFOLFOX6 for six cycles has no clinical benefit.
Ishibashi, K., Ishida, H., Kuwabara, K., Ohsawa, T., Okada, N., Yokoyama, M., & Kumamoto, K. (2014). Short-term intravenous antimicrobial prophylaxis for elective rectal cancer surgery: Results of a prospective randomized non-inferiority trial. Surgery Today, 44, 716–722.
To investigate the effects of single-dose versus multiple-dose antimicrobial prophylaxis on surgical site infections (SSI) in patients undergoing elective surgery for rectal cancer
All patients received a preoperative bowel cleansing, kanamycin and erythromycin orally within 24 hours prior to surgery, and 1 g of a second-generation cephalosporin IV perioperatively. After surgery, patients were randomized to receive either single-dose prophylaxis one hour after surgery or an additional five doses over two consecutive days. Wounds were inspected daily in the hospital and in the clinic 30 days after surgery. The trial was designed to detect a 10% difference in the incidence of SSIs between groups.
Noninferiority randomized, controlled trial
The incidence of incision site infections was 5% in the single-dose group and 7.1% in the multiple-dose group. Organ/space infections were 10.8% in the single-dose group and 8.6% in the multiple-dose group. Several organ/space infections were related to anastomotic dehiscence. Overall, the incidence of SSIs was 13.7% with single-dose prophylaxis and 13.6% with multiple-dose prophylaxis. Subgroup analysis by specific surgical procedure did not show any significant differences between groups.
Single-dose, postoperative, intravenous, antimicrobial prophylaxis demonstrated similar results to that of multiple-dose prophylaxis. Multiple antimicrobial doses did not show improved benefit for the prevention of surgical site infections
A single dose of IV antibiotic prophylaxis after rectal surgery for cancer had similar outcomes to that of multiple postoperative antibiotic doses. These findings show there is no benefit to more doses of prophylactic postoperative antibiotics for the prevention of SSIs.
Isaacs, C., Robert, N.J., Bailey, F.A., Schuster, M.W., Overmoyer, B., Graham, M., . . . Kaye, J.A. (1997). Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. Journal of Clinical Oncology, 15, 3368–3377.
Patients were assigned randomly to receive either placebo or interleukin-11 (IL-11) 50 mcg/kg/day subcutaneous (SC). The study drug was blinded. Randomization was stratified by investigative site and also by whether patients had received any prior chemotherapy. SC administration began on day two and was given for a minimum of 10 days after the first cycle of chemotherapy.
Sixty-seven patients were assessable. Sixty-eight percent of patients in the IL-11 group did not receive transfusions, versus 41% in the placebo group (p = .04). The IL-11 group had a decreased total number of platelet transfusions (p = .03) and time to platelet recovery to greater than 50K in the second cycle (p = .01). Side effects in the IL-11 group (p < .05) were peripheral edema (68%), dyspnea (48%), pleural effusion (18%), and conjunctival infection (25%).
Irwin, M.L., Cartmel, B., Gross, C.P., Ercolano, E., Li, F., Yao, X., . . . Ligibel, J. (2015). Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. Journal of Clinical Oncology, 33, 1104–1111.
To examine the effects of an exercise intervention on the severity of aromatase inhibitor (AI)-induced arthralgia in women with breast cancer
Patients were randomly assigned to a year-long exercise program consisting of twice weekly supervised resistance training and home-based aerobic exercise for 150 minutes per week. Participants wore heart rate monitors during workouts, and after each exercise session, participants recorded exercise type, duration, and average heart rate in logs. The aerobic component was usually brisk walking although patients could choose other activities such as stationary bike use. Strength training consisted of six exercises with gradually increasing weight. Women in the usual care group were instructed to continue usual activities. Those in the usual care group received monthly phone calls to determine AI adherence.
Randomized, controlled trial
Women assigned to exercise increased their physical activity by an average of 159 minutes per week compared to an average of 49 minutes per week in the usual care group (p < 0.001). Over 12 months, worst joint pain decreased by 29% in the exercise group while usual care patients showed a 3% increase (p < 0.001). The same patterns were shown in the DASH and osteoarthritis index measures. There was no dose response from exercise effects on arthralgia pain or functional measures. Adherence to AIs was 76% in the usual care group and 80% in the exercise group. AI-associated joint pain worsened slightly over time in the usual care group. The strongest benefit of exercise was seen after 12 months.
The findings of this study suggested that an exercise program including aerobic, resistance, and strength training may reduce pain from arthralgia caused by AIs among women with breast cancer.
Exercise has been recommended for patients with cancer to ameliorate multiple symptoms. This study showed that exercise also can reduce arthralgia-related pain associated with AIs and improve function among breast cancer survivors. Nurses can educate patients regarding the numerous benefits of exercise and can encourage and recommend regular exercise.
Irani, J., Salomon, L., Oba, R., Bouchard, P., & Mottet, N. (2010). Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncology, 11(2), 147-154.
Compare the efficacy of 3 drugs in preventing hot flashes in men receiving hormone treatment for prostate cancer
Patients were randomly assigned to receive wither venlafaxine delayed release 75 mg/day, medroxyprogesterone 20 mg/day or cyproterone acetate 100 mg/day in addition to leuprorelin injections. Patients were followed up at 4, 8 and 12 weeks. Patients completed daily hot flush diaries and categorised hot flush severity
Double blind randomized controlled trial
Patients in the medroxyprogesterone group had higher hot flash scores at baseline. The reduction in daily hot flush scores at 4 weeks was significantly lower for all 3 groups (p<.0001). Improvements were significantly lower in the venlafaxine group than either of the other 2 groups ( p = .0006), and patients ratings of efficacy of treatment showed that significantly fewer patients in the venlafaxine group rated the treatment as good ( p<.0001) compared to the other 2 groups. Adverse events related to the study drugs were not significantly different between groups, though cyproterone led to a non significantly higher number of vascular adverse events. The most frequent adverse events were gastrointestinal, including pain, constipation, diarrhea and nausea. GI events were more frequent with venlafaxine.
Men with significant hot flushes during androgen suppression for prostate cancer appeared to respond better to cyproterone acetate and medroxyprogesterone acetate than to venlafaxine
It appears that hormonal treatment is more effective in than venlafaxine for management of hot flashes in patients who are receiving androgen suppression for prostate cancer. Results also showed that many men did not seek treatment for this problem, suggesting that nurses may need to directly assess these patients for problems with hot flash symptoms. Effects of steroidal anti androgens on prostate cancer are not clear, and patients receiving both androgen suppression and cyproterone or medroxyprogesterone could have increases in prostate specific antigen concentrations.